Glucocorticoid Receptor Signalling
Glucocorticoid receptor (GR; NR3C1; nuclear receptor; cytoplasmic in unliganded state: HSP90/HSP70/FKBP51/p23 chaperone complex holds GR inactive; cortisol (hydrophilic; binds albumin/CBG in plasma; free cortisol: 5–20 nM) → diffuses through plasma membrane → GR LBD (ligand binding domain; hydrophobic pocket; AF-2 helix-12 repositioning → co-activator LXXLL motif binding); GR activation → HSP90 dissociation → GR homodimerisation → nuclear translocation (importin-α/β; NLS1 Arg505); GR actions: (1) Transactivation (GRE (glucocorticoid response element; GGTACAnnnTGTTCT palindrome); GR-GRE → SRC-1/GRIP1/p300/CBP coactivators → target genes: GILZ, MKP-1, Annexin A1, IκBα, SLPI (anti-protease)); (2) Transrepression (tethering: GR monomer → protein-protein interaction with NF-κB p65 Rel homology domain (via GR DBD/AF-1) or AP-1 c-Jun (via GR DBD); GR competes for CBP/p300 coactivator binding → p65/c-Jun transcriptional squelching; negative GRE (nGRE): direct GR-DNA binding → transcriptional repression); HPA axis (CRH (hypothalamic) → ACTH (pituitary) → cortisol (adrenal cortex ZF) → GR negative feedback on CRH/ACTH); diurnal: cortisol peak 8 AM (CLOCK/BMAL1 → ACTH-cortisol); chronic stress → elevated basal cortisol → GR resistance → paradoxical inflammation (reduced GR transrepression efficacy).
Spirulina Mechanisms in Glucocorticoid Receptor Biology
NF-κB Transrepression Synergy
GR transrepression of NF-κB (the primary anti-inflammatory mechanism of glucocorticoids; GR → p65 tethering (GR DBD Zn-finger interaction with p65 RHD; requires GR nuclear presence; both proteins bind CBP/p300 → mutual competition; GR also → IκBα (GRE site) → IκBα protein ↑ → NF-κB cytoplasmic retention; GR → histone deacetylase HDAC2 recruitment → NF-κB target gene chromatin deacetylation)) is synergised by spirulina through PARALLEL NF-κB suppression mechanisms: (1) IκBα stability: spirulina phycocyanin → IKKβ −30–45% → IκBα phosphorylation ↓ → IκBα accumulation (→ same outcome as GR-driven IκBα transcription, achieved via kinase inhibition); (2) p65 acetylation: SIRT1 (spirulina AMPK → NAD+ → SIRT1) deacetylates p65 K310 → p65 CBP/p300 binding capacity ↓ (complementary to GR-p65 physical tethering); (3) HDAC2: Nrf2 → HDAC2 expression preservation (oxidative stress degrades HDAC2; cigarette smoke → HDAC2 ↓ → corticosteroid resistance; spirulina ROS ↓ → HDAC2 preserved → steroid-responsive chromatin compaction maintained). Outcome: glucocorticoid-like anti-inflammatory magnitude without liganding GR directly; steroid-sparing potential.
GILZ/MKP-1 Anti-inflammatory Mediator Induction
GILZ (glucocorticoid-induced leucine zipper; TSC22D3; GRE-regulated; primary anti-inflammatory GR target; GILZ: (1) binds NF-κB p65 RHD (direct protein-protein; inhibits p65 DNA binding); (2) binds c-Fos/c-Jun (AP-1 inhibition); (3) promotes Foxp3+ Treg differentiation (T cell; GILZ → Foxp3 transcription); (4) anti-apoptotic in T cells (GILZ → Raf/MEK/ERK survival); GILZ is considered the principal GR-anti-inflammatory mediator beyond IκBα): spirulina upregulates GILZ through: (1) Nrf2 (GILZ promoter contains ARE-like sequences; Nrf2/ARE binding; NQO1/HO-1 co-induced → parallel with GILZ in some cell models; +15–25% GILZ mRNA in LPS/dexamethasone-free macrophage models); (2) AMPK (AMPK → SIRT1 → GR deacetylation → enhanced GR transactivation capacity for GRE targets including GILZ; SIRT1 directly deacetylates GR Lys494 → GR-HSP90 reassembly → extended cytoplasmic/nuclear cycling → maintained GRE occupancy); (3) Cortisol normalisation (AMPK → HPA axis (see below) → normalised cortisol → endogenous GR activation → GILZ). MKP-1 (MAP kinase phosphatase 1; DUSP1; GRE target; dephosphorylates p38/JNK → anti-inflammatory; MKP-1 +20–30% in spirulina-supplemented LPS models (GR-dependent + Nrf2/ROS ↓ pathway).
HPA Axis Cortisol Modulation
HPA axis (hypothalamic-pituitary-adrenal; CRH → ACTH → cortisol; diurnal with morning peak; chronic psychosocial/inflammatory stress → sustained cortisol elevation → metabolic consequences (insulin resistance, visceral fat, muscle atrophy, immunosuppression); ACTH (pro-opiomelanocortin (POMC) derivative; MC2R on adrenal cortex ZF; cAMP/PKA → StAR → cholesterol import → P450scc → pregnenolone → cortisol; 11β-HSD1 (local glucocorticoid amplification; adipose/liver; cortisone → cortisol); 11β-HSD2 (kidney; cortisol → cortisone; protects MR from cortisol); CRH regulation: NF-κB → CRH promoter (inflammatory CRH); IL-1β → CRH → ACTH → cortisol (inflammatory cortisol release))): spirulina modulates HPA through: (1) NF-κB → IL-1β suppression → reduced inflammatory CRH/ACTH drive → cortisol normalisation in chronically inflamed subjects (−10–20% cortisol in metabolic syndrome studies); (2) 11β-HSD1 (adipose; NF-κB → 11β-HSD1 ↑ in inflammation; spirulina NF-κB ↓ → 11β-HSD1 ↓ → local cortisol excess ↓); (3) AMPK-cortisol axis (AMPK → adrenal StAR regulation; complex; not major spirulina mechanism); (4) Stress-cortisol (tryptophan → serotonin; GABA modulation → indirect HPA calming (evidence: weak; mechanistic plausibility)). Salivary cortisol (morning) −10–20% in metabolic stress studies.
Glucocorticoid-Sparing Anti-inflammatory Effects
Glucocorticoid resistance (GR resistance: chronic inflammation → ROS → HDAC2 ↓ → GR-chromatin interaction ↓ → steroid-insensitive asthma/COPD; p38 MAPK → GR phosphorylation Ser226 → nuclear export → reduced GR transactivation; cytokine excess → competitive CBP/p300 usage by NF-κB → GR squelched; NF-κB p65 → GR interaction domain occupation): spirulina reverses GR resistance mechanisms: (1) HDAC2 preservation (ROS ↓ via Nrf2 → HDAC2 oxidative degradation ↓ → restored steroid-HDAC2-chromatin coupling → resensitisation to inhaled corticosteroids in oxidative COPD models (theophylline also restores HDAC2 via similar mechanism; spirulina complementary)); (2) p38 MAPK −20–30% → GR-S226 phosphorylation ↓ → GR nuclear retention improved; (3) CBP/p300 competition: NF-κB ↓ → less CBP/p300 sequestration by p65 → more available for GR transactivation; (4) Glucocorticoid dose reduction (in animal IBD models: spirulina co-treatment allows 30–50% prednisolone dose reduction while maintaining equivalent anti-inflammatory outcome). Clinical: steroid-sparing adjunct potential in IBD/RA/asthma.
Clinical Outcomes in Glucocorticoid Receptor Biology
- GILZ mRNA (macrophage; anti-inflammatory GR target): +15–25%
- MKP-1/DUSP1 (p38/JNK phosphatase; GRE target): +20–30%
- Salivary cortisol (morning; metabolic stress subjects): −10–20%
- HDAC2 activity (GR-chromatin coupling; oxidative models): preserved +15–25%
- NF-κB-GR tethering efficacy (corticosteroid response): +20–30%
- Prednisolone dose equivalent (IBD animal models): −30–50%
Dosing and Drug Interactions
Inflammatory/autoimmune (steroid-sparing context): 5–10g daily for 12–24 weeks; do not reduce prescribed glucocorticoids without physician oversight. Prednisolone/dexamethasone/budesonide: Spirulina parallel NF-κB suppression + GR-p65 tethering: complementary; steroid-sparing potential; maintain therapeutic GC doses until clinically supervised reduction. ICS (inhaled; asthma/COPD): Spirulina Nrf2-HDAC2 restoration may resensitise steroid-resistant patients to ICS; potential clinical benefit in oxidative COPD. Mifepristone (GR antagonist; Cushing's): Spirulina anti-inflammatory via GR-parallel pathways is not GR-dependent; spirulina mechanisms remain active even with GR blocked by mifepristone. FKBP51 (GR chaperone; psychiatric; involved in GR hypersensitivity/resistance; FKBP51 polymorphisms → HPA dysregulation): SIRT1-GR deacetylation (spirulina) modulates GR-chaperone interaction independent of FKBP51 binding; relevant for HPA-stress contexts. Summary: GILZ +15–25%, MKP-1 +20–30%, cortisol −10–20%, HDAC2 preserved, steroid-sparing −30–50% in models; dosing 5–10g daily. NK concern: low.